The Human Medicines Regulations 2012 explained for UK teams
The Human Medicines Regulations 2012 cover UK product authorisation, prescribing, supply, conditional pharmacy exemptions and shortage protocols.
The Human Medicines Regulations 2012 (SI 2012/1916) govern UK human medicines, including manufacture, distribution, product authorisation, prescribing and supply. They also cover packaging and leaflets. Exceptions are conditional and activity-specific. The revised contents show where each set of requirements sits.
Authorising a product, dispensing it against a prescription and administering it are separate legal questions. But an exception that permits one activity does not automatically permit the others, as the different routes in regulation 226A and regulation 238 illustrate.
Human Medicines Regulations 2012 summary
Use this map to find the relevant provisions. It covers the main areas discussed here, rather than every part of the instrument. The locations come from the official revised contents.
| Activity or question | Where to start |
|---|---|
| Manufacture, import and wholesale distribution | Part 3 |
| Product authorisation requirements and marketing authorisations | Parts 4 and 5 |
| Exceptions to product authorisation requirements | Part 10 |
| Prescribing, sale, supply, administration and related exemptions | Part 12 |
| Packaging and patient leaflets | Part 13 |
The Regulations do not remove the need to consult surviving provisions of the Medicines Act 1968. For example, regulation 4 links specified exemptions to the conditional pharmacy routes in section 10 of that Act.
Product authorisation and activity licences are separate
Start with the product. Regulation 46 prohibits sale or supply without the required authorisation or registration, subject to statutory exceptions. It also restricts supply outside the terms of that authorisation or registration. Part 10 contains exceptions, so a marketing authorisation is not required for every medicine.
Then check the activity. Regulation 17 generally requires an appropriate manufacturer's licence for manufacture or assembly and sets import requirements. Regulation 18 generally requires a wholesale dealer's licence for wholesale distribution, or holding medicines for that purpose. Import requirements also need a separate check against the relevant territory and exceptions.
A product authorisation does not replace a manufacturer's or wholesale dealer's licence.
Human Medicines Regulations 2012 prescription requirements
Under regulation 214, the starting rule for a prescription-only medicine is supply against a prescription from an appropriate practitioner. The provision identifies practitioners and restrictions, and is subject to exemptions. Listed professionals do not all have identical prescribing powers. Regulation 214 also deals separately with parenteral administration.
Regulation 217 sets general prescription requirements. These include patient and prescriber particulars, signature and writing requirements, and the patient's age if under 12. Its general dispensing period is six months, with provisions for repeatable prescriptions.
That six-month period is not a universal validity rule for every prescription. The provision accommodates separate electronic-prescription and approved-country requirements. Do not turn its general wording into a wet-ink-only rule, or assume that all controlled-drug prescriptions last six months. Those details require their own checks rather than a general prescription checklist based on regulation 217 alone.
For pharmacy transactions, regulation 220 generally connects sale or supply with a lawful retail pharmacy business and registered pharmacy premises. It includes supervision and authorised-transaction provisions. It does not require a pharmacist to personally supervise every handover.
Regulation 220B, inserted on 7 January 2026, permits a conditional authorised transaction while a pharmacist is absent or treated as absent. Treated as absent includes being at the pharmacy but unavailable, or not positioned to intervene. The medicine must already have been dispensed by or under a pharmacist's supervision and be ready for sale or supply. The pharmacist authorises another person to transact, subject to conditions, restrictions and patient-safety considerations. This is not a general delegation of the clinical check, and it is not a technician-supervision permission.
Pharmacy preparation and special medicinal products
Pharmacy preparation is another route with its own limits. Section 10 of the Medicines Act 1968 contains conditional provisions for pharmacy preparation, dispensing and assembly. Read it alongside regulation 4, rather than assuming pharmacies have a blanket exemption from licensing and authorisation.
Special medicinal products have a separate conditional route under regulation 167. Its conditions include an unsolicited order, a specified prescriber's requirements, a patient's special needs and direct treatment responsibility. Advertising restrictions, records and applicable licensing conditions also matter.
Do not merge this route with pharmacy preparation or prescribing outside an authorised medicine's terms. Identify which provision the proposed activity relies on before assessing its conditions.
What Schedules 17 and 19 permit
The two schedules answer different questions. One concerns specified exemptions for particular persons and medicines. The other concerns administration to save life in an emergency.
Schedule 17 exemptions
Schedule 17 sets out particular persons, medicines and conditions. Match the proposed activity to the relevant entry. A professional title alone does not establish that every medicine or transaction is covered.
For example, the schedule includes specified school procurement of emergency inhalers and adrenaline. That does not create unrestricted prescribing authority. An exemption from a prescription requirement also does not automatically remove separate pharmacy-sale restrictions. Read the relevant entry with regulation 235, rather than using the schedule as a general permission list.
Schedule 19 emergency administration
Under regulation 238, regulation 214(2) does not apply to a Schedule 19 medicine administered "for the purpose of saving life in an emergency". Schedule 19 includes glucagon, glucose and hydrocortisone injections, and naloxone products.
This exception concerns administration. It does not provide general authority to prescribe, sell or supply the listed medicines. Use the distinction when assessing emergency arrangements, without treating the schedule as clinical dosing guidance.
Regulation 226A and Serious Shortage Protocols
Regulation 226A provides a conditional exemption from the prescription-supply rule in regulation 214(1). A Serious Shortage Protocol, or SSP, is ministerially issued in response to an actual or anticipated serious shortage.
Supply must be through a person lawfully conducting a retail pharmacy business, by or under a pharmacist's supervision, and it must comply with the protocol and satisfy its requirements. The pharmacist must also judge that departing from the prescription is reasonable and appropriate.
An SSP may permit a different strength, quantity or pharmaceutical form, or specified substitution with another medicine. It must state its period and territorial application. Regulation 226A does not itself waive the product-authorisation requirements in regulation 46 or the administration restriction in regulation 214(2).
A stock shortage alone doesn't give a pharmacy unrestricted power to change a prescription. Locate the applicable protocol and check its current terms on the NHSBSA SSP page. NHSBSA also stresses professional judgement, patient agreement and changing protocol validity. A list entry or expiry date cannot replace reading the protocol's conditions.
Where to check changes and get a PDF
For a Human Medicines Regulations 2012 PDF, start with the official revised contents and version controls. An original "as made" PDF records the original instrument. It is a poor substitute for the current consolidated text.
MHRA guidance states that it regulates medicines through UK-wide marketing authorisations from 1 January 2025. This does not erase every Great Britain and Northern Ireland manufacturing, import or operational distinction. A retained PLGB prefix alone does not establish a current GB-only authorisation scope.
For each proposed activity, check the revised provision, any exception relied on, and the amendment and commencement information. A cross-reference to a provision is not enough to establish when it took effect. This overview is not legal clearance for an individual supply.
RegAffairs AI offers a linked answer on what UK human medicines rules cover. For an SSP transaction, the applicable protocol still determines the permitted departure from the prescription under regulation 226A.